Ecolab Inc. (ECL) Falls 3.03% for February 05

Equities Staff |

One of the S&P 500’s big losers for Friday February 05 was Ecolab Inc. (ECL). The company’s stock fell 3.03% to $105.86 on volume of 927,885 shares.

The stock opened the day at 108.89 and traded between a low of $105.81 and a high of $108.89. The stock finished the day down $3.31 per share. Ecolab Inc. has an average daily volume of 1.36 million and a total float of 295.3 million shares. The 50-day SMA for Ecolab Inc. is $111.39 and its 200-day SMA is $113.21. The high for the stock over the last 52 weeks is $122.48 and the low is $99.99.

Ecolab Inc develops and markets cleaning and sanitizing premium programs, products and services for the hospitality, foodservice, healthcare, industrial and energy markets.

Ecolab Inc. is centered in St. Paul, MN, and has 47,000 employees. Today’s trading day leaves the company with a market cap of $31.26 billion. The company has a P/S ratio of n/a, P/B ratio of 4.61, and a 71.1.

For a complete fundamental analysis analysis of Ecolab Inc., check out’s Stock Valuation Analysis report for ECL. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…